What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call

Halozyme (HALO) Q3 2026 Earnings Call Transcript

Merck patent setbacks in the U.S. cloud an otherwise strong quarter for royalties.

What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call

Halozyme Therapeutics (NASDAQ:HALO) raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions from newer subcutaneous drug launches. Total revenue rose 39% to $493 million from $354.3 million a y

HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Total Revenue Increased 39% YOY to $493 million

Halozyme Therapeutics Raises 2026 Revenue Outlook After Q3 Beat

Third-quarter revenue rose 39% year over year to $493 million, while non-GAAP earnings per share reached $2.39, 3 cents above estimates.

HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE - PressReach

Total Revenue Increased 39% YOY to $493 millionRoyalty Revenue Increased 44% YOY to $341 million Raising 2026 Financial Guidance Ranges:Total Revenue of $1.860 – $1.925 billion, YOY Growth of 33% – 38%Royalty Revenue of $1.235 – $1.255 billion, YOY Growth of 42% – 45%Adjusted EBITDA of $1.240 – $1.290 billion, YOY Growth of 89% – … Continue reading "HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE"